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Background
Current evidence suggests that inhaled glucocorticoids
(IGC) have a more profound topical none genomic effect
on bronchial airways as compared to systemic glucocorti-
coids. The value of adding IGC to current therapy of acute
asthma is not well established.
Methods
We conducted a double-blind, randomized, two-arm,
parallel groups, controlled clinical trial to compare the
addition of budesonide 1500 mcg or placebo (normal
saline) to standard acute asthma treatment (albuterol and
ipratropium bromide) administered in 3 divided mixed
doses within 1 hour in the emergency department (ED).
Children 2-12 years of age with moderate or severe acute
asthma, scoring 8-15/15 on a well-validated scoring system
were included. Both groups received a single dose of
prednisone 2 mg/kg/day (max. 60 mg) at the beginning of
therapy. The primary outcome was admission rate within
2-4 hours from starting therapy.
Results
A total of 723 children were enrolled in the study over
17 months duration, of whom 139 were allowed to re-enroll
and be randomized to constitute 906 randomization assign-
ments (458 on the treatment group and 448 on the control
group); with baseline mean + SD asthma score of 10.63 +
1.73; age 5.52 + 2.76 years; 35% girls; 30.8% (16.5%) with
baseline severe asthma score of ≥12 (≥ 13). Statistical Ana-
lysis plan allowed for the potential dependency in response
due to reenrollments of a subset of children, using General-
ized Linear Mixed Modeling (GLMM) techniques. Baseline
demographic and clinical characteristics were not signifi-
cantly different between the two randomized groups.
Seventy-five out of 458 (16.4%) of the treatment group vs.
82/448 (18.3%) of the control group were admitted, (OR
0.85, CI: 0.59-1.23, p-value=0.39). Among the severe asth-
matics with baseline score ≥13, treatment vs. placebo
group, GLMM adjusted admission rate was 30% vs. 47%,
indicating a 17% difference in admission rate in favor of the
treatment group (adjusted OR of 0.49, CI: 0.25-0.95;
p-value= 0.035) that indicated a 51% reduction in the risk
of admission for the treatment vs. control group.
Conclusions
Children with baseline severe asthma score ≥13 who
were treated with budesonide had a significant reduction
in their admission rate.
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